BioSpace News Archive

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is indicated.

Droplet Biosciences today announced an $8 million seed investment to establish proof of concept for the company’s technology.

Perimeter Medical Imaging AI, Inc. announced that it will participate in the upcoming International Conference on Surgical Cancer Care hosted by the Society of Surgical Oncology (SSO), with a spotlight presentation in the HUB Theater and featuring demos on the S-Series OCT device in the HUB exhibit hall.

Simulations Plus, Inc. today announced that chief executive officer Shawn O’Connor will be presenting at the Sidoti Small-Cap Investor Conference taking place virtually on March 22-23, 2023.

Accelus today announced that the U.S. Food & Drug Administration (FDA) has issued a 510(k) clearance to Accelus for its Remi® Robotic Navigation System for use with GE OEC 9900 C-Arm fluoroscopic imaging systems.

GeneDx Holdings Corp. announced new research at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting which demonstrates exome sequencing’s diagnostic advantages in shortening patients’ and families’ diagnostic odysseys when compared with chromosomal microarray.

Microbot Medical Inc., which is rapidly scaling up its internal capabilities with globally renowned members joining its Scientific Advisory Board, announced that Professor Mark W. Little, BSc, MSc, MBBS, DipIPEM, FHEA, FRCR, FCIRSE, has joined the SAB, becoming the first member from the United Kingdom.

Alpha Pro Tech, Ltd., a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, announced financial results for the three month period and year ended December 31, 2022.

ObvioHealth and Mi-Helper, Inc. announce a partnership to conduct a decentralized clinical trial for a non-invasive neuromodulation device for the treatment of migraines.

Glenmark Specialty SA, the subsidiary of Glenmark Pharmaceuticals Ltd., an innovation-driven, global pharmaceuticals company received acceptance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application for GRC 54276 to proceed with a Phase 1/2, first-in-human, clinical study of GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas.